Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy

Mai Zhi-peng; Yan* Wei-gang; Li Han-zhong; Zhou Yi; Zhou Zhi-en

Your Location：

Home >

Browse articles >

Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy

中国医学科学杂志（英文版） 2015年30卷第3期页码：143-149

Orginal Article | Updated：2024-04-10

- Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy
- Affiliations：
  
  Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Author bio：
- Funds：
- DOI：
  中图分类号：
- 网络出版日期：2015-06-20，
  
  纸质出版日期：2015-06
- Accepted：
Scan QR Code
Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy[J]. 中国医学科学杂志（英文版）, 2015,30(3):143-149.

Mai Zhi-peng, Yan* Wei-gang, Li Han-zhong, et al. Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy[J]. Chinese medical sciences journal, 2015, 30(3): 143-149.
Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy[J]. 中国医学科学杂志（英文版）, 2015,30(3):143-149. DOI：

Mai Zhi-peng, Yan* Wei-gang, Li Han-zhong, et al. Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy[J]. Chinese medical sciences journal, 2015, 30(3): 143-149. DOI：

摘要

Abstract

Objective

To evaluate the outcomes of T3a prostate cancer with unfavorable prognostic factors treated with permanent interstitial brachytherapy combined with external radiotherapy and hormone therapy.

Methods

From January 2003 to December 2008

38 patients classified as T3a prostate cancer with unfavorable prognostic factors were treated with trimodality therapy (brachytherapy + external radiotherapy + hormone therapy). The prescription dose of brachytherapy and external radiotherapy were 110 Gy and 45 Gy

respectively. The duration of hormone therapy was 2-3 years. The endpoints of this study included biochemical failure-free survival (BFFS)

distant metastasis-free survival (DMFS)

cancer-specific survival (CSS)

and overall survival (OS). Survival curves were calculated using the Kaplan-Meier method. The Log-rank test was used to identify the prognostic predictors for univariate analysis.

Results

The median follow-up was 71 months. The serum pre-treatment prostate-specific antigen (PSA) level ranged from 10.0 to 99.8 ng/ml (mean 56.3 ng/ml)

the Gleason score ranged from 5 to 9 (median 8)

and the percentage of positive biopsy cores ranged from 10% to 100% (mean 65%). The 5-year BFFS

DMFS

CSS

and OS rates were 44%

69%

82%

and 76%

respectively. All biochemical failures occurred within 40 months. The percentage of positive biopsy cores was significantly correlated with BFFS

DMFS

and OS (all

=0.000)

and the Gleason score with DMFS (

=0.000) and OS (

=0.001).

Conclusions

T3a prostate cancer with unfavorable prognostic factors presents not so optimistic outcome. Hormone therapy should be applied to prolong the biochemical progression-free or metastasis-free survival. The percentage of positive biopsy cores and the Gleason score are significant prognostic factors.

关键词

Keywords

references

Konstantinos H. Prostate cancer in the elderly. Int Urol Nephrol 2005 ; 37 : 797 - 806 .

Torre LA , Bray F , Siegel RL , et al. Global cancer statistics, 2012. CA Cancer J Clin 2015 ; 65 : 87 - 108 .

Chen YC , Chuang CK , Hsieh ML , et al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: an experience in Taiwan. Urology 2007 ; 70 : 101 - 5 .

Sridharan S , Dal Pra A , Catton C , et al. Locally advanced prostate cancer: current controversies and optimisation opportunities. Clin Oncol (R Coll Radiol) 2013 ; 25 : 499 - 505 .

Bolla M , Collette L , Blank L , et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002 ; 360 : 103 - 6 .

van den Ouden D , Hop WC , Schröder FH . Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998 ; 160 : 1392 - 7 .

Lee LN , Stock RG , Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002 ; 52 : 444 - 52 .

Stock RG , Cahlon O , Cesaretti JA , et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2004 ; 59 : 1352 - 9 .

Nickers P , Coppens L, de Leval J, et al. 192 Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial. Radiother Oncol 2006 ; 79 : 329 - 34 .

Pellizzon AC , Salvajoli J , Novaes P , et al. The relationship between the biochemical control outcomes and the quality of planning of high-dose rate brachytherapy as a boost to external beam radiotherapy for locally and locally advanced prostate cancer using the RTOG-ASTRO Phoenix definition. Int J Med Sci 2008 ; 5 : 113 - 20 .

Stock RG , Cesaretti JA , Hall SJ , et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radio- therapy and hormonal therapy. BJU Int 2009 ; 104 : 1631 - 6 .

Davis BJ , Horwitz EM , Lee WR , et al. American Brachy- therapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012 ; 11 : 6 - 19 .

Mohler JL , Armstrong AJ , Bahnson B , et al. Prostate cancer, Version 3. 2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012 ; 10 : 1081 - 7 .

Sylvester J , Blasko JC , Grimm P , et al. Interstitial implantation techniques in prostate cancer. J Surg Oncol 1997 ; 66 : 65 - 75 .

American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997 ; 37 : 1035 - 41 .

Shao YH , Demissie K , Shih W , et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst 2009 ; 101 : 1280 - 3 .

Pilepich MV , Winter K , Lawton CA , et al. Androgen sup- pression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 ; 61 : 1285 - 90 .

Pistis F , Guedea F , Pera J , et al. External beam radio- therapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy 2010 ; 9 : 15 - 22 .

Hsu IC , Cabrera AR , Weinberg V , et al. Combined modality treatment with high-dose-rate brachytherapy boost for locally advanced prostate cancer. Brachy- therapy 2005 ; 4 : 202 - 6 .

Carpenter TJ , Forsythe K , Kao J , et al. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Brachytherapy 2011 ; 10 : 261 - 8 .

21.Shilkrut M , McLaughlin PW , Merrick GS , et al. Treatment outcomes in very high-risk prostate cancer treated by dose-escalated and combined-modality radiation therapy . Am J Clin Oncol 2014 Feb 10. [2015-01-01].

Fioriti D , Mischitelli M , Di Monaco F , et al. Cancer stem cells in prostate adenocarcinoma: a target for new anticancer strategies. J Cell Physiol 2008 ; 216 : 571 - 5 .

Ishiyama H , Satoh T , Kitano M , et al. High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term hormonal therapy for high-risk and very high-risk prostate cancer: outcomes after 5-year follow-up. J Radiat Res 2014 ; 55 : 509 - 17 .

Galalae RM , Martinez A , Mate T , et al. Long-term outcome by risk factors using conformal high-dose-rate brachy- therapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004 ; 58 : 1048 - 55 .

浏览量

1444

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

关联资源

Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy